SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:uu-307293"
 

Sökning: onr:"swepub:oai:DiVA.org:uu-307293" > Sequence variation ...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00005707naa a2200553 4500
001oai:DiVA.org:uu-307293
003SwePub
008161111s2016 | |||||||||||000 ||eng|
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-3072932 URI
0247 a https://doi.org/10.1093/carcin/bgw0732 DOI
040 a (SwePub)uu
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Sclafani, Francescou Royal Marsden NHS Fdn Trust, Dept Med, Sutton SM2 5PT, Surrey, England.4 aut
2451 0a Sequence variation in mature microRNA-608 and benefit from neo-adjuvant treatment in locally advanced rectal cancer patients
264 c 2016-07-05
264 1b Oxford University Press (OUP),c 2016
338 a print2 rdacarrier
520 a Single nucleotide polymorphisms (SNPs) in microRNA genes have been associated with colorectal cancer (CRC) risk, survival and response to treatment. Conflicting results are available on the association between rs4919510, a SNP in mature miR-608 and clinical outcome in CRC. Here, we analyzed the association between rs4919510 and benefit from perioperative treatment in a randomised phase II trial of neoadjuvant Capecitabine and Oxaliplatin (CAPOX) followed by chemo-radiotherapy, surgery and adjuvant CAPOX +/- Cetuximab in high-risk locally advanced rectal cancer (LARC). A total of 155/164 (94.5%) patients were assessable. 95 (61.3%) were homozygous for CC, 55 (35.5%) heterozygous (CG) and 5 (3.2%) homozygous for GG. Median follow-up was 64.9 months. In the CAPOX arm the 5-year progression-free survival (PFS) and overall survival (OS) rates were 54.6% and 60.7% for CC and 82.0% and 82.1% for CG/GG, respectively (HR PFS 0.13, 95% CI: 0.12-0.83, P = 0.02; HR OS 0.38, 95% CI: 0.14-1.01, P = 0.05). In the CAPOX-C arm PFS and OS were 73.2 and 82.2%, respectively for CC carriers and 64.6 and 73.1% for CG/GG carriers (HR PFS 1.38, 95% CI: 0.61-3.13, P = 0.44; HR OS 1.34, 95% CI: 0.52-3.48, P = 0.55). An interaction was found between study treatment and rs4919510 genotype for both PFS (P = 0.02) and OS (P = 0.07). This is the first study investigating rs4919510 in LARC. The CC genotype appeared to be associated with worse prognosis compared to the CG/GG genotype in patients treated with chemotherapy and chemo-radiotherapy alone. Addition of Cetuximab to chemotherapy and chemo-radiotherapy in CC carriers appeared to improve clinical outcome.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
7001 a Chau, Ianu Royal Marsden NHS Fdn Trust, Dept Med, Sutton SM2 5PT, Surrey, England.4 aut
7001 a Cunningham, Davidu Royal Marsden NHS Fdn Trust, Dept Med, Sutton SM2 5PT, Surrey, England.4 aut
7001 a Lampis, Andreau Inst Canc Res, Dept Mol Pathol, Sutton SM2 5NG, Surrey, England.4 aut
7001 a Hahne, Jens Clausu Inst Canc Res, Dept Mol Pathol, Sutton SM2 5NG, Surrey, England.4 aut
7001 a Ghidini, Micheleu Inst Canc Res, Dept Mol Pathol, Sutton SM2 5NG, Surrey, England.4 aut
7001 a Lote, Hazelu Royal Marsden NHS Fdn Trust, Dept Med, Sutton SM2 5PT, Surrey, England.;Inst Canc Res, Dept Mol Pathol, Sutton SM2 5NG, Surrey, England.4 aut
7001 a Zito, Domenicou Inst Canc Res, Dept Mol Pathol, Sutton SM2 5NG, Surrey, England.4 aut
7001 a Tabernero, Josepu Univ Autonoma Barcelona, Vall Hebron Univ Hosp, Dept Med Oncol, Barcelona 08035, Spain.4 aut
7001 a Glimelius, Bengtu Uppsala universitet,Experimentell och klinisk onkologi4 aut0 (Swepub:uu)bengglim
7001 a Cervantes, Andresu Univ Valencia, Biomed Res Inst INCLIVA, Dept Haematol & Med Oncol, Valencia 46010, Spain.4 aut
7001 a Begum, Ruwaidau Royal Marsden NHS Fdn Trust, Dept Med, Sutton SM2 5PT, Surrey, England.4 aut
7001 a De Castro, David Gonzalezu Royal Marsden NHS Fdn Trust, Dept Med, Sutton SM2 5PT, Surrey, England.4 aut
7001 a Wilson, Sanna Hulkkiu Royal Marsden NHS Fdn Trust, Dept Med, Sutton SM2 5PT, Surrey, England.4 aut
7001 a Peckitt, Clareu Royal Marsden NHS Fdn Trust, Dept Med, Sutton SM2 5PT, Surrey, England.4 aut
7001 a Eltahir, Zakariau Royal Marsden NHS Fdn Trust, Dept Med, Sutton SM2 5PT, Surrey, England.4 aut
7001 a Wotherspoon, Andrewu Royal Marsden NHS Fdn Trust, Dept Med, Sutton SM2 5PT, Surrey, England.4 aut
7001 a Tait, Dianau Royal Marsden NHS Fdn Trust, Dept Med, Sutton SM2 5PT, Surrey, England.4 aut
7001 a Brown, Ginau Royal Marsden NHS Fdn Trust, Dept Med, Sutton SM2 5PT, Surrey, England.4 aut
7001 a Oates, Jacquelineu Royal Marsden NHS Fdn Trust, Dept Med, Sutton SM2 5PT, Surrey, England.4 aut
7001 a Braconi, Chiarau Royal Marsden NHS Fdn Trust, Dept Med, Sutton SM2 5PT, Surrey, England.;Inst Canc Res, Dept Canc Therapeut, Sutton SM2 5NG, Surrey, England.4 aut
7001 a Valeri, Nicolau Royal Marsden NHS Fdn Trust, Dept Med, Sutton SM2 5PT, Surrey, England.;Inst Canc Res, Dept Mol Pathol, Sutton SM2 5NG, Surrey, England.4 aut
7102 a Royal Marsden NHS Fdn Trust, Dept Med, Sutton SM2 5PT, Surrey, England.b Inst Canc Res, Dept Mol Pathol, Sutton SM2 5NG, Surrey, England.4 org
7730 t Carcinogenesisd : Oxford University Press (OUP)g 37:9, s. 852-857q 37:9<852-857x 0143-3334x 1460-2180
8564 u https://academic.oup.com/carcin/article-pdf/37/9/852/17295202/bgw073.pdf
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-307293
8564 8u https://doi.org/10.1093/carcin/bgw073

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy